For healthcare professionals. Compounded preparations are dispensed on a doctor’s prescription.
Short answer: Tadalafil 5 mg once daily was studied in a 2018 systematic review and meta-analysis of 13 placebo-controlled trials, which combined lower urinary tract symptom (LUTS) and erectile dysfunction outcomes and reported improvement in LUTS over 12 weeks. Organic nitrates must not be combined with tadalafil, and alpha-blocker co-prescription needs blood pressure caution.
The indication and the active
This guide concerns lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), the indication for which the regimen below was studied. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor. A 2003 record describes it as “tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t(1/2)) of 17.5 h” (Journal of the American College of Cardiology, 2003; PMID 14642699).

What the evidence shows
The 2018 systematic review and meta-analysis identified 13 randomised, double-blind, placebo-controlled trials comparing tadalafil 5 mg once daily with placebo, involving 3973 patients. It was a combined analysis of LUTS and erectile dysfunction outcomes (Lower Urinary Tract Symptoms, 2018; PMID 29341503). Its abstract states that “tadalafil 5 mg once-daily was effective in improving LUTS suggestive of BPH” over 12 weeks (PMID 29341503). For the LUTS outcome, total International Prostate Symptom Score, the pooled estimate was SMD = -2.02, 95% CI -2.52 to -1.53, in favour of tadalafil (PMID 29341503). The abstract describes the regimen as well tolerated, and it also reports a discontinuation signal: discontinuations due to adverse event OR 1.79, 95% CI 1.12-2.85, P = 0.01 versus placebo (PMID 29341503).
| Study | Regimen | Outcome as reported | PMID |
|---|---|---|---|
| Systematic review and meta-analysis of 13 placebo-controlled RCTs, 3973 patients, combined LUTS and erectile dysfunction analysis (2018) | Tadalafil 5 mg once daily, 12 weeks | LUTS outcome: total IPSS SMD -2.02 (95% CI -2.52 to -1.53) versus placebo | 29341503 |
The review pooled placebo comparisons only. It therefore does not establish how tadalafil compares with an alpha-blocker, and the evidence it reports is for the 5 mg once-daily regimen.
Safety: organic nitrates
Tadalafil should not be combined with organic nitrates. The 2003 study records that “similar to other PDE5 inhibitors, tadalafil should not be administered in combination with organic nitrates” (PMID 14642699). In that study, “the hemodynamic interaction between tadalafil and sublingual nitroglycerin lasted 24 h, but was not seen at 48 h and beyond” (PMID 14642699). Nitrate use should therefore be asked about before any tadalafil prescription is issued.
Safety: alpha-blockers
A 2006 crossover study in 18 healthy middle-aged men reports that “when co-administered with alpha1-blockers, PDE-5 inhibitors could induce orthostatic hypotension” (Urology, 2006; PMID 16765179). In the same study, tadalafil 20 mg with alfuzosin 10 mg daily “showed no clinically relevant hemodynamic interactions” (PMID 16765179). Because that study was small and enrolled healthy men, each patient on an alpha-blocker needs an individual assessment of orthostatic symptoms and blood pressure before a tadalafil prescription is written.
Forms Lynnity prepares
Lynnity holds tadalafil USP in its formulary and prepares it as a capsule or an oral liquid for one named patient on a doctor’s prescription. The prescriber sets the strength, the quantity and the directions. The safety studies cited here used 20 mg: seven consecutive daily doses of 20 mg in the nitrate study (PMID 14642699), and a single 20 mg dose in the alpha-blocker study (PMID 16765179). The 5 mg once-daily figure applies only to the meta-analysis of placebo-controlled trials (PMID 29341503).
What the prescription must state
- The patient’s name, for a named-patient preparation
- The active: tadalafil USP
- The form: capsule or oral liquid
- The strength, quantity and directions, set by the prescriber
- Current nitrate use, and current alpha-blocker therapy with the blood pressure assessment
For the separate erectile dysfunction question, see Tadalafil for Erectile Dysfunction: What the 2026 Evidence Shows for Malaysian Prescribers, and for compounded PDE5 formulations more broadly, Compounded Erectile Dysfunction Formulations.
How to prescribe
The prescription is written by a doctor registered in Malaysia. It must name the patient and state the tadalafil, the strength, the form, the quantity and the directions, and it should record nitrate and alpha-blocker use. Preparations are made under Good Compounding Practice (GCP) at the Lynnity compounding laboratory in Kuala Lumpur.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).
A urology clinic that is setting up a tadalafil prescription for a named patient can take the prescribing question to a Lynnity pharmacist through the contact page.
Frequently asked questions
What did the 2018 meta-analysis of tadalafil for LUTS and erectile dysfunction include?
It included 13 randomised, double-blind, placebo-controlled trials comparing tadalafil 5 mg once daily with placebo, involving 3973 patients, in a combined analysis of LUTS and erectile dysfunction outcomes (PMID 29341503). For the LUTS outcome, its abstract reports that tadalafil 5 mg once daily was effective in improving lower urinary tract symptoms suggestive of benign prostatic hyperplasia. The review compared tadalafil with placebo only.
Can tadalafil be given with a nitrate?
No. The 2003 study records that tadalafil should not be administered in combination with organic nitrates, and that the blood pressure interaction with sublingual nitroglycerin lasted 24 hours (PMID 14642699). Nitrate use should be asked about before any prescription is issued.
Can tadalafil be used with an alpha-blocker?
The abstract of a 2006 crossover study reports that PDE-5 inhibitors given with alpha1-blockers could induce orthostatic hypotension (PMID 16765179). In that small study of healthy men, tadalafil 20 mg with alfuzosin 10 mg daily showed no clinically relevant hemodynamic interaction. Each patient needs an individual assessment of orthostatic symptoms.
What must a compounded tadalafil prescription specify?
It must name the patient and the active, tadalafil USP, with the strength, form (capsule or oral liquid), quantity and directions set by the prescriber. It should also record nitrate use and current alpha-blocker therapy. It is issued by a doctor registered in Malaysia and prepared under Good Compounding Practice (GCP).

